CY1119837T1 - Στερεα διασπορα - Google Patents

Στερεα διασπορα

Info

Publication number
CY1119837T1
CY1119837T1 CY20171101121T CY171101121T CY1119837T1 CY 1119837 T1 CY1119837 T1 CY 1119837T1 CY 20171101121 T CY20171101121 T CY 20171101121T CY 171101121 T CY171101121 T CY 171101121T CY 1119837 T1 CY1119837 T1 CY 1119837T1
Authority
CY
Cyprus
Prior art keywords
solid dispersion
pyridv
dihydroxazol
quinazolin
triazolo
Prior art date
Application number
CY20171101121T
Other languages
English (en)
Inventor
David Shank FRY
Christopher M. Lindemann
Michael PREIGH
Corey Jay BLOOM
Christopher Donovan Craig
Devon Brevard DUBOSE
Jeff GAUTSCHI
Dan SMITHEY
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of CY1119837T1 publication Critical patent/CY1119837T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Glass Compositions (AREA)
  • Inorganic Insulating Materials (AREA)
  • Optical Communication System (AREA)

Abstract

Στο παρόν παρέχονται στερεά διασπορά Ν4- (4-( [1,2,4]τριαζολο[1,5-α]πυριδιv-7-υλοξυ)-3-μεθυλοφαινυλ)-Ν6- (4,4-διμεθυλ-4, 5-διϋδροοξαζολ-2-υλ) κιναζολιν-4,6-διαμίνης και διεργασίες για την παρασκευή της στερεάς διασποράς. Επίσης, στο παρόν παρέχονται φαρμακευτική σύνθεση που περιλαμβάνει στερεά διασπορά Ν4- (4-([1,2,4]τριαζολο[1,5-α]πυριδιv-7-υλοξυ)-3-μεθυλοφαινυλ) -Ν6- (4,4-διμεθυλ-4,5-διϋδροοξαζολ-2-υλ)κιναζολιν-4, 6-διαμίνης και χρήσεις αυτής.
CY20171101121T 2011-10-14 2017-10-30 Στερεα διασπορα CY1119837T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547620P 2011-10-14 2011-10-14
US201261606207P 2012-03-02 2012-03-02
PCT/US2012/060044 WO2013056108A2 (en) 2011-10-14 2012-10-12 Solid dispersion

Publications (1)

Publication Number Publication Date
CY1119837T1 true CY1119837T1 (el) 2018-06-27

Family

ID=47471981

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101121T CY1119837T1 (el) 2011-10-14 2017-10-30 Στερεα διασπορα

Country Status (31)

Country Link
US (5) US9457093B2 (el)
EP (1) EP2765990B1 (el)
JP (2) JP5944514B2 (el)
KR (1) KR102000312B1 (el)
CN (3) CN103998023B (el)
AU (3) AU2012322039C1 (el)
BR (2) BR122020010643B1 (el)
CA (2) CA2852058C (el)
CL (1) CL2014000930A1 (el)
CO (1) CO6960547A2 (el)
CR (1) CR20140228A (el)
CY (1) CY1119837T1 (el)
DK (1) DK2765990T3 (el)
ES (1) ES2650608T3 (el)
HR (1) HRP20171578T1 (el)
HU (1) HUE035247T2 (el)
IL (1) IL232103B (el)
LT (1) LT2765990T (el)
ME (1) ME02913B (el)
MX (1) MX353970B (el)
MY (1) MY169072A (el)
NO (1) NO2021029I1 (el)
PL (1) PL2765990T3 (el)
PT (1) PT2765990T (el)
RS (1) RS56608B1 (el)
RU (1) RU2648448C2 (el)
SG (1) SG11201401459YA (el)
SI (1) SI2765990T1 (el)
TW (3) TWI594769B (el)
WO (1) WO2013056108A2 (el)
ZA (1) ZA201606123B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116875C2 (uk) 2011-10-14 2018-05-25 Еррей Біофарма Інк. Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
BR122020010643B1 (pt) * 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
RU2018138976A (ru) * 2012-03-23 2018-12-06 Эррэй Биофарма Инк. Лечение рака головного мозга
EP3763702B1 (en) * 2013-07-19 2023-12-13 Siga Technologies, Inc. Preparation of amorphous tecovirimat dispersions
EP3082803A4 (en) * 2013-12-20 2017-05-31 Phosphorex Inc. Indirubin solid dispersion composition
RU2696578C1 (ru) 2014-02-05 2019-08-05 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
WO2016198983A1 (en) * 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
WO2017148391A1 (zh) 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
AU2018246258B2 (en) 2017-03-30 2021-07-29 Merck Patent Gmbh Pharmaceutical formulation
JP7328151B2 (ja) 2017-04-28 2023-08-16 シージェン インコーポレイテッド Ｈｅｒ２陽性がんの処置
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
SG11202007287XA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of mastocytosis
KR20240140193A (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
US11708463B2 (en) * 2018-04-06 2023-07-25 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
MX2022003254A (es) * 2019-09-19 2022-04-18 Forma Therapeutics Inc Composiciones activadoras de piruvato cinasa r (pkr).
EP4048275A1 (en) 2019-10-21 2022-08-31 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
CN114945369A (zh) 2019-11-15 2022-08-26 思进公司 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
AU2020419197B2 (en) * 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
IL298538A (en) 2020-05-29 2023-01-01 Seagen Inc Methods for treating her2-positive cancer with tocatinib in combination with trastuzumab and oxaliplatin-based chemotherapy
CA3189333A1 (en) 2020-07-29 2022-02-03 Seagen Inc. Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
CN115340541B (zh) * 2022-07-01 2024-01-30 上海艾洋化学科技有限公司 一种妥卡替尼中间体的制备方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
CN115650977A (zh) * 2022-10-09 2023-01-31 广东润兴生物科技有限公司 一种妥卡替尼的合成方法
WO2024191826A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer using anti-her2 antibody-drug conjugates and her2 kinase inhibitors
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
PL362979A1 (en) * 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
CA2431322A1 (en) * 2000-12-11 2002-06-20 Eiji Nara Medicinal compositions having improved absorbability
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
AU2004264937B2 (en) 2003-08-14 2010-04-29 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
PA8629301A1 (es) * 2004-04-08 2006-10-13 Wyeth Corp Formulaciones de acetato de bezedoxifeno
SI2090575T1 (sl) * 2005-11-15 2011-08-31 Array Biopharma Inc Postopki in intermediati za pripravo N4-fenil-kinazolin-4-aminskih derivatov
WO2008133102A1 (ja) * 2007-04-20 2008-11-06 Daido Chemical Corporation 新規乾式固体分散体用基剤、該基剤を含有する固体分散体及び該分散体を含有する組成物
CA2686756A1 (en) 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
CA2700673A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
US9004752B2 (en) * 2008-05-05 2015-04-14 Abbvie, Inc. Method for evaluating the solubility of a crystalline substance in a polymer
EP2158912A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2253306A1 (en) * 2009-05-18 2010-11-24 Royal College of Surgeons in Ireland Orodispersible dosage forms containing solid drug dispersions
BR122020010643B1 (pt) * 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
UA116875C2 (uk) 2011-10-14 2018-05-25 Еррей Біофарма Інк. Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
RU2018138976A (ru) 2012-03-23 2018-12-06 Эррэй Биофарма Инк. Лечение рака головного мозга

Also Published As

Publication number Publication date
JP2014528484A (ja) 2014-10-27
NZ624942A (en) 2016-06-24
US9457093B2 (en) 2016-10-04
EP2765990A2 (en) 2014-08-20
RS56608B1 (sr) 2018-02-28
CA2852058C (en) 2021-06-01
CA3114454C (en) 2022-11-29
PL2765990T3 (pl) 2018-01-31
JP2016027062A (ja) 2016-02-18
KR102000312B1 (ko) 2019-07-15
ME02913B (me) 2018-04-20
TW201330876A (zh) 2013-08-01
MX2014004551A (es) 2015-02-12
WO2013056108A2 (en) 2013-04-18
AU2017210499A1 (en) 2017-08-17
US20210220361A1 (en) 2021-07-22
BR112014009092A2 (pt) 2017-04-18
ES2650608T3 (es) 2018-01-19
US20140296267A1 (en) 2014-10-02
RU2014119283A (ru) 2015-11-20
PT2765990T (pt) 2017-11-14
IL232103B (en) 2018-11-29
IL232103A0 (en) 2014-05-28
LT2765990T (lt) 2018-01-25
CO6960547A2 (es) 2014-05-30
CA3114454A1 (en) 2013-04-18
TWI594769B (zh) 2017-08-11
AU2017210499B2 (en) 2019-01-24
HUE035247T2 (hu) 2018-05-02
AU2017210499C1 (en) 2021-04-29
BR112014009092B1 (pt) 2022-01-18
AU2012322039C1 (en) 2021-04-29
JP5944514B2 (ja) 2016-07-05
NO2021029I1 (no) 2021-07-09
AU2012322039B2 (en) 2017-08-17
ZA201606123B (en) 2021-05-26
DK2765990T3 (da) 2017-11-13
BR122020010643B1 (pt) 2022-05-17
TWI722189B (zh) 2021-03-21
TW202131902A (zh) 2021-09-01
RU2648448C2 (ru) 2018-03-26
CN103998023B (zh) 2018-06-15
CN103998023A (zh) 2014-08-20
US20170136022A1 (en) 2017-05-18
AU2019200243A1 (en) 2019-01-31
EP2765990B1 (en) 2017-09-06
TWI788733B (zh) 2023-01-01
AU2019200243B2 (en) 2020-06-11
CN108498465A (zh) 2018-09-07
KR20140075798A (ko) 2014-06-19
SG11201401459YA (en) 2014-07-30
MX353970B (es) 2018-02-07
AU2012322039A1 (en) 2014-06-05
CN114886853A (zh) 2022-08-12
SI2765990T1 (sl) 2017-11-30
US20230097309A1 (en) 2023-03-30
AU2019200243C1 (en) 2021-04-29
MY169072A (en) 2019-02-12
CN108498465B (zh) 2022-05-17
TW201728323A (zh) 2017-08-16
CA2852058A1 (en) 2013-04-18
WO2013056108A3 (en) 2013-06-27
HRP20171578T1 (hr) 2017-12-01
CR20140228A (es) 2014-08-21
CL2014000930A1 (es) 2014-07-18
US20190275043A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
CY1119837T1 (el) Στερεα διασπορα
CY1120885T1 (el) Παραγωγα πυρρολο[3,2-d]πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
BR112014009084A2 (pt) polimorfos de arry-380, inibidor seletivo de herb2 e composições farmacêuticas que contenham os mesmos
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
CL2015001358A1 (es) Potenciadores del cftr deuterados
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
PH12015502780B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
BR112013025987A2 (pt) derivados de pirimidina para o tratamento de infecções virais
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112014018918A8 (pt) Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais
CL2014002497A1 (es) Uso de n4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina o (2-((4-((4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)amino)quinazolin-6-il)amino)-4-metil-4,5-dihidrooxazol-4-il)metanol para el tratamiento contra el cancer cerebral metastasico o local.
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
CR20130293A (es) Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
CY1119391T1 (el) Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης
CL2014001323A1 (es) Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
ES2409805R1 (es) Nueva sal de un derivado de pirimidina
MX2015015845A (es) Derivados de pirimidin-4-il)-oxi)-1h-indol-1-carboxamida y uso de los mismos.
UA111383C2 (uk) Тверда дисперсія